NEW ADVANCES IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS

2015

TUESDAY, OCTOBER 13, 2015
8:00 AM – 12:30 PM

LOCATION: Valley Forge Casino Resort
1160 First Avenue • King of Prussia, PA 19406

PRESENTED BY: Temple University, University of Pittsburgh, University of Pennsylvania, Geisinger Health System, and Penn State Milton S. Hershey Medical Center

PROGRAM DESCRIPTION:
The median survival of idiopathic pulmonary fibrosis (IPF) patients is 2.5 to 3.5 years after diagnosis. However, the clinical course of disease varies considerably from slow progression over many years to acute exacerbation, rapid loss of lung function, and early death. This program is designed to provide knowledge on new medical advances for IPF that include recent approval of therapies. In addition, it will provide information about different clinical trials that are ongoing to improve the survival rate and quality of life of IPF patients.

EDUCATIONAL OBJECTIVES:
At the conclusion of this CME activity, participants should be able to:
• Employ the most recent evidence based diagnostic algorithms in evaluating and treating patients with idiopathic pulmonary fibrosis
• Employ the appropriate diagnostic testing to exclude secondary causes of ILD
• Provide information on the latest clinical trial studies available
• Understand the importance of early referral to lung transplant centers and palliative care

TARGETED AUDIENCE:
Pulmonologists, PCPs, Respiratory Therapists, Physician Assistants, Nurse Practitioners, and Nurses involved in the treatment of IPF

ACCREDITATION STATEMENT:
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for Physicians.

NURSING ACCREDITATION STATEMENT:
Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Registered Nurses will receive up to 4.5 Contact Hours

CERTIFICATION STATEMENT:
Temple University School of Medicine designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY:
It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

DETAILS:
PROGRAM DESCRIPTION: The median survival of idiopathic pulmonary fibrosis (IPF) patients is 2.5 to 3.5 years after diagnosis. However, the clinical course of disease varies considerably from slow progression over many years to acute exacerbation, rapid loss of lung function, and early death. This program is designed to provide knowledge on new medical advances for IPF that include recent approval of therapies. In addition, it will provide information about different clinical trials that are ongoing to improve the survival rate and quality of life of IPF patients.

EDUCATIONAL OBJECTIVES: At the conclusion of this CME activity, participants should be able to:
- Employ the most recent evidence based diagnostic algorithms in evaluating and treating patients with idiopathic pulmonary fibrosis
- Employ the appropriate diagnostic testing to exclude secondary causes of ILD
- Provide information on the latest clinical trial studies available
- Understand the importance of early referral to lung transplant centers and palliative care

TARGETED AUDIENCE: Pulmonologists, PCPs, Respiratory Therapists, Physician Assistants, Nurse Practitioners, and Nurses involved in the treatment of IPF

ACCREDITATION STATEMENT: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for Physicians.

NURSING ACCREDITATION STATEMENT: Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Registered Nurses will receive up to 4.5 Contact Hours

CERTIFICATION STATEMENT: Temple University School of Medicine designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY: It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.
**PROGRAM DESCRIPTION:**
The median survival of idiopathic pulmonary fibrosis (IPF) patients is 2.5 to 3.5 years after diagnosis. However, the clinical course of disease varies considerably from slow progression over many years to acute exacerbation, rapid loss of lung function, and early death.

This program is designed to provide knowledge on new medical advances for IPF that include recent approval of therapies. In addition, it will provide information about different clinical trials that are ongoing to improve the survival rate and quality of life of IPF patients.

**EDUCATIONAL OBJECTIVES:**
At the conclusion of this CME activity, participants should be able to:
- Employ the most recent evidence-based diagnostic algorithms in evaluating and treating patients with idiopathic pulmonary fibrosis
- Employ the appropriate diagnostic testing to exclude secondary causes of ILD
- Provide information on the latest clinical trial studies available
- Understand the importance of early referral to lung transplant centers and palliative care

**TARGETED AUDIENCE:**
Pulmonologists, PCPs, Respiratory Therapists, Physician Assistants, Nurse Practitioners, and Nurses involved in the treatment of IPF

**ACCREDITATION STATEMENT:**
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for Physicians.

**NURSING ACCREDITATION STATEMENT:**
Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Registered Nurses will receive up to 4.50 Contact Hours

**CERTIFICATION STATEMENT:**
Temple University School of Medicine designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**DISCLOSURE POLICY:**
It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

**NEW ADVANCES IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS**

**TUESDAY, OCTOBER 13, 2015**
**8:00 AM – 12:30 PM**

**LOCATION:** Valley Forge Casino Resort
1160 First Avenue • King of Prussia, PA 19406

**PRESENTED BY:** Temple University, University of Pittsburgh, University of Pennsylvania, Geisinger Health System, and Penn State Milton S. Hershey Medical Center
New Advances in the Management of Idiopathic Pulmonary Fibrosis

Program Agenda:

7:00 AM – 8:00 AM
Registration and Continental Breakfast

8:00 AM – 8:10 AM
Welcome and Introduction
Michelle Vega-Olivo, CRNP

8:10 AM – 8:30 AM
Definition and Epidemiology of IPF
Gerard J. Criner, MD, FACP, FACCp

8:30 AM – 8:50 AM
Pathology of IPF
Kevin F. Gibson, MD

8:50 AM – 9:10 AM
HRCT in IPF
Scott Simpson, DO

9:10 AM – 9:30 AM
Staging of IPF
Francis Cordova, MD

9:30 AM – 9:50 AM
Clinical Presentation and Management in IPF
Gregory Tino, MD

9:50 AM – 10:10 AM
Environmental Considerations
Rebecca Bascom, MD

10:10 AM – 10:30 AM
Break

10:30 AM – 10:50 AM
New Pharmacologic Treatment
Namrata Patel, MD

10:50 AM – 11:10 AM
Non-Pharmacologic Treatment
Michelle Vega-Olivo, CRNP

11:10 AM – 11:30 AM
Investigative Approach and Referring Your Patient to Research
Paul F. Simonnell, MD, PhD, FCCP

11:30 AM – 11:50 AM
Transplantation
Akira Shiose, MD, PhD

11:50 AM – 12:05 PM
Palliative Care
Kathleen O. Lindell, PhD, RN

12:05 PM – 12:15 PM
Role of IPP Community Support Groups
Jennifer H. Wescoe, M.Ed., NCC

12:15 PM – 12:30 PM
Q & A Session
Daniel J. Kass, MD

12:30 PM
Lunch

Course Director:

Gerald J. Criner, MD, FACP, FACCp
Professor, Thoracic Medicine and Surgery
Director, Medical Intensive Care Unit
and Ventilator Rehabilitation Unit
Co-Director, Center for Inflammation,
Translational and Clinical Lung Research
Temple University School of Medicine

Namrata Patel, MD
Associate Professor,
Thoracic Medicine and Surgery
Temple University School of Medicine

Paul F. Simonelli, MD, PhD, FCCP
Director, Thoracic Medicine
Fellowship Program Director
Associate Director,
Pulmonary Critical Care Service Line
Geisinger Medical Center

Scott Simpson, DO
Assistant Professor, Clinical Radiology
Department of Radiology
Temple University School of Medicine

Gregory Tino, MD
Associate Professor of Medicine,
Director, Pulmonary Outpatient Practices,
Hospital of the University of Pennsylvania,
Philadelphia, PA

Akira Shiose, MD, PhD
Assistant Professor, Surgery
Associate Director,
Mechanical Circulatory Support
Director, ECMO
Temple University Hospital

Michelle Vega-Olivo, MSN, CRNP, FNP-BC
Pulmonary Nurse Practitioner
Temple Lung Center

Jennifer H. Wescoe, M.Ed., NCC
Founder, Executive Director of
The Wescoe Foundation for
Pulmonary Fibrosis

Course Faculty:

Rebecca Bascom, MD, MPH
Professor of Medicine
Penn State College of Medicine,
Hershey Pulmonary Medicine

Kevin F. Gibson, MD
Professor of Medicine
Clinical Director,
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Kevin E. Gibson, MD
Professor of Medicine
Clinical Director,
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Francis Cordova, MD
Professor, Thoracic Medicine and Surgery
Medical Director,
Lung Transplantation Program
Temple University Health System

Daniel J. Kass, MD
Director, Dorothy P. and Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Kathleen O. Lindell, PhD, RN
Research Assistant Professor
Clinical Nurse Specialist
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Jennifer H. Wescoe, M.Ed., NCC
Founder, Executive Director of
The Wescoe Foundation for
Pulmonary Fibrosis

How did you hear about this program?

Name:

Degree:

Specialty:

Address:

City: State: Zip:

Daytime Phone:

If you have special needs that we can address to make your participation more meaningful and enjoyable, please contact our office at 215-707-4787.
New Advances in the Management of Idiopathic Pulmonary Fibrosis

Registration is Free. Seating is Limited – Registration is Required. Lunch will be provided.

Program Agenda:

7:00 AM – 8:00 AM
Registration and Continental Breakfast

8:00 AM – 8:10 AM
Welcome and Introduction
Michelle Vega-Olivo, CRNP

8:10 AM – 8:30 AM
Definition and Epidemiology of IPF
Gerard J. Criner, MD, FACP, FACCNP

8:30 AM – 8:50 AM
Pathology of IPF
Kevin F. Gibson, MD

8:50 AM – 9:10 AM
HRCT in IPF
Scott Simpson, DO

9:10 AM – 9:30 AM
Staging of IPF
Francis Cordova, MD

9:30 AM – 9:50 AM
Clinical Presentation and Management in IPF
Gregory Tino, MD

9:50 AM – 10:10 AM
Environmental Considerations
Rebecca Bascom, MD

10:10 AM – 10:30 AM
Break

10:30 AM – 10:50 AM
New Pharmacologic Treatment
Namrata Patel, MD

10:50 AM – 11:10 AM
Non-Pharmacologic Treatment
Michelle Vega-Olivo, CRNP

11:10 AM – 11:30 AM
Investigative Approach and Referring Your Patient to Research
Paul F. Simonelli, MD, PhD, FCCP

11:30 AM – 11:50 AM
Transplantation
Akira Shiose, MD, PhD

11:50 AM – 12:05 PM
Palliative Care
Kathleen O. Lindell, PhD, RN

12:05 PM – 12:15 PM
Role of IPF Community Support Groups
Jennifer H. Wescoe, M.Ed., NCC

12:15 PM – 12:30 PM
Q & A Session
Daniel J. Kass, MD

12:30 PM
Lunch

COURSE DIRECTOR:
Gerard J. Criner, MD, FACP, FACCNP
Professor, Thoracic Medicine and Surgery
Director, Medical Intensive Care Unit
and Ventilator Rehabilitation Unit
Co-Director, Center for Inflammation,
Translational and Clinical Lung Research
Temple University School of Medicine

Namrata Patel, MD
Associate Professor, Thoracic Medicine and Surgery
Temple University School of Medicine

Paul F. Simonelli, MD, PhD, FCCP
Director, Thoracic Medicine
Fellowship Program Director
Associate Director,
Pulmonary Critical Care Service Line
Geisinger Medical Center

Scott Simpson, DO
Assistant Professor, Clinical Radiology
Department of Radiology
Temple University School of Medicine

Gregory Tino, MD
Associate Professor of Medicine,
Director, Pulmonary Outpatient Practices,
Hospital of the University of Pennsylvania,
Philadelphia, PA

Akira Shiose, MD, PhD
Assistant Professor, Surgery Associate Director
Associate Director,
Mechanical Circulatory Support
Director, ECMO
Temple University Hospital

Michelle Vega-Olivo, MSN, CRNP, FNP-BC
Pulmonary Nurse Practitioner
Temple Lung Center

Jennifer H. Wescoe, M.Ed., NCC
Founder, Executive Director of
The Wescoe Foundation for Pulmonary Fibrosis

COURSE FACULTY:
Rebecca Bascom, MD, MPH
Professor of Medicine
Penn State College of Medicine,
Hershey Pulmonary Medicine

Francis Cordova, MD
Professor, Thoracic Medicine and Surgery
Medical Director,
Lung Transplantation Program
Temple University Health System

Kevin F. Gibson, MD
Professor of Medicine
Clinical Director,
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Daniel J. Kass, MD
Director, Dorothy P. and Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Kathleen O. Lindell, PhD, RN
Research Assistant Professor
Clinical Nurse Specialist
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Jennifer H. Wescoe, M.Ed., NCC
Founder, Executive Director of
The Wescoe Foundation for Pulmonary Fibrosis

How did you hear about this program?

- If you have special needs that we can address to make your participation more meaningful and enjoyable, please contact our office at (215) 707-4787.
NEW ADVANCES IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS

2015

PROGRAM AGENDA:

7:00 AM – 8:00 AM Registration and Continental Breakfast
8:00 AM – 8:10 AM Welcome and Introduction
Michelle Vega-Olivo, CRNP
8:10 AM – 8:30 AM Definition and Epidemiology of IPF
Gerard J. Criner, MD, FACP, FACC
8:30 AM – 8:50 AM Pathology of IPF
Kevin F. Gibson, MD
8:50 AM – 9:10 AM HRCT in IPF
Scott Simpson, DO
9:10 AM – 9:30 AM Staging of IPF
Francis Cordova, MD
9:30 AM – 9:50 AM Clinical Presentation and Management in IPF
Gregory Tino, MD
9:50 AM – 10:10 AM Environmental Considerations
Rebecca Bascom, MD
10:10 AM – 10:30 AM Break
10:30 AM – 10:50 AM New Pharmacologic Treatment
Namrata Patel, MD
10:50 AM – 11:10 AM Non-Pharmacologic Treatment
Michelle Vega-Olivo, CRNP
11:10 AM – 11:30 AM Investigative Approach and Referring Your Patient to Research
Paul F. Simonelli, MD, PhD, FCCP
11:30 AM – 11:50 AM Transplantation
Akira Shiose, MD, PhD
11:50 AM – 12:05 PM Palliative Care
Kathleen O. Lindell, PhD, RN
12:05 PM – 12:15 PM Role of IPF Community Support Groups
Jennifer H. Wescoe, M.Ed., NCC
12:15 PM – 12:30 PM Q & A Session
Daniel J. Kass, MD
12:30 PM Lunch

2015 NEW ADVANCES IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS

REGISTRATION FORM

REGISTRATION IS FREE. SEATING IS LIMITED – REGISTRATION IS REQUIRED LUNCH WILL BE PROVIDED.

RETURN TO:
Walter J. Moore
Office for Continuing Medical Education
Temple University School of Medicine
3440 N. Broad Street, Kresge 100
Philadelphia, PA 19140
215-707-4787 or 800-23-TUCME or FAX 215-707-8268
Register online at www.temple.edu/cme

How did you hear about this program?

NAME:

DEGREE:

SPECIALTY:

ADDRESS:

CITY: STATE: ZIP:

DAYTIME PHONE:

If you have special needs that we can address to make your participation more meaningful and enjoyable, please contact our office at (215) 707-4787.

COURSE DIRECTOR:

Gerard J. Criner, MD, FACP, FACC
Professor, Thoracic Medicine and Surgery
Director, Medical Intensive Care Unit
and Ventilator Rehabilitation Unit
Co-Director, Center for Inflammation,
Translational and Clinical Lung Research
Temple University School of Medicine

Namrata Patel, MD
Associate Professor,
Thoracic Medicine and Surgery
Temple University School of Medicine

Paul F. Simonelli, MD, PhD, FCCP
Director, Thoracic Medicine
Fellowship Program Director
Associate Director,
Pulmonary Critical Care Service Line
Geisinger Medical Center

Scott Simpson, DO
Assistant Professor, Clinical Radiology
Department of Radiology
Temple University School of Medicine

Gregory Tino, MD
Associate Professor of Medicine,
Director, Pulmonary Outpatient Practices,
Hospital of the University of Pennsylvania,
Philadelphia, PA

Akira Shiose, MD, PhD
Assistant Professor, Surgery
Associate Director
Mechanical Circulatory Support
Director, ECMO
Temple University Hospital

Michelle Vega-Olivo, MSN, CRNP, FNP-BC
Pulmonary Nurse Practitioner
Temple Lung Center

Jennifer H. Wescoe, M.Ed., NCC
Founder, Executive Director of
The Wescoe Foundation for Pulmonary Fibrosis

COURSE FACULTY:

Rebecca Bascom, MD, MPH
Professor of Medicine
Penn State College of Medicine,
Hershey Pulmonary Medicine

Francis Cordova, MD
Professor, Thoracic Medicine and Surgery
Medical Director,
Lung Transplantation Program
Temple University Health System

Kevin F. Gibson, MD
Professor of Medicine
Clinical Director,
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Daniel J. Kass, MD
Director, Dorothy P. and Richard P. Simmons Center
for Interstitial Lung Diseases
Assistant Professor of Medicine
UPMC Montefiore Hospital

Kathleen O. Lindell, PhD, RN
Research Assistant Professor
Clinical Nurse Specialist
Dorothy P. & Richard P. Simmons Center
for Interstitial Lung Disease
UPMC Montefiore Hospital

Jennifer H. Wescoe, M.Ed., NCC
Founder, Executive Director of
The Wescoe Foundation for Pulmonary Fibrosis

How did you hear about this program?
New Advances in the Management of Idiopathic Pulmonary Fibrosis

Tuesday, October 13, 2015
8:00 AM – 12:30 PM

Location: Valley Forge Casino Resort
1160 First Avenue • King of Prussia, PA 19406

Presented by: Temple University, University of Pittsburgh, University of Pennsylvania, Geisinger Health System, and Penn State Milton S. Hershey Medical Center

Program Description:
The median survival of idiopathic pulmonary fibrosis (IPF) patients is 2.5 to 3.5 years after diagnosis. However, the clinical course of disease varies considerably from slow progression over many years to acute exacerbation, rapid loss of lung function, and early death. This program is designed to provide knowledge on new medical advances for IPF that include recent approval of therapies. In addition, it will provide information about different clinical trials that are ongoing to improve the survival rate and quality of life of IPF patients.

Educational Objectives:
At the conclusion of this CME activity, participants should be able to:
• Employ the most recent evidence based diagnostic algorithms in evaluating and treating patients with idiopathic pulmonary fibrosis
• Employ the appropriate diagnostic testing to exclude secondary causes of ILD
• Provide information on the latest clinical trial studies available
• Understand the importance of early referral to lung transplant centers and palliative care

Targeted Audience:
Pulmonologists, PCPs, Respiratory Therapists, Physician Assistants, Nurse Practitioners, and Nurses involved in the treatment of IPF

Accreditation Statement:
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for Physicians.

Nursing Accreditation Statement:
Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Registered Nurses will receive up to 4.50 Contact Hours

Certification Statement:
Temple University School of Medicine designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

Disclosure Policy:
It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.